Navigation Links
ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action
Date:11/10/2008

VANCOUVER, British Columbia, Nov. 10 /PRNewswire-FirstCall/ -- ProtoKinetix Inc. (OTC Bulletin Board: PKTX), a biotech company focused on the research, development and commercialization of patented anti-aging glycopeptides (AAGPs(TM)) announced today that its Director of Science Dr. Geraldine Deliencourt has received results of tests conducted by a major independent laboratory in France to determine the biological activity of AAGP(TM) on the selectin inflammation pathway. The highly specific tests conducted on selectin showed 100% adhesion inhibition. Diseases such as Alzheimer's, Chron's, diabetes, arthritis, cancer and cardiovascular problems are among the many life-threatening conditions treated with anti-inflammation and selectin inhibition therapies.

These results are consistent with previous tests conducted using extremely hostile stresses. Repeatedly, the presence of AAGP(TM) has shown its ability to protect cells under the most adverse of conditions. Dr. Deliencourt said, "The results obtained broaden the impact and scope of the applications of AAGP(TM). They will also help us clarify the mechanism of action of AAGP(TM) and seem to be consistent with all of the previous results we have obtained." She further explains that these results indicate that AAGP(TM) could be both an adhesion inhibitor and an anti-oxidant.

Ross Senior, President and CEO of ProtoKinetix, said, "The control of inflammation is of vital importance to the treatment of a number of immune complex mediated diseases. AAGP(TM) continues to demonstrate its potential to become a major contributor in the successful treatment of a wide range of health problems."

About ProtoKinetix

ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycoproteins (AAGP(TM)) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialogue with major corporations and institutions who have contacted the company about the broad range of applications for AAGP(TM) products. For more detailed information, please visit our website at http://www.protokinetix.com.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.

Company contact: Investor Relations contact:

Blair Henderson, ProtoKinetix, Inc. Rick McCaffrey, OTC Financial Network

604-687-9887 781-444-6100x625

info@protokinetix.com rick@otcfn.com

http://www.otcfn.com/pktx


'/>"/>
SOURCE ProtoKinetix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base
2. OTC Financial Network Issues Corporate Profile on ProtoKinetix Inc.
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
7. IsoTis Receives FDA Clearance for Accell Family of Products
8. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
9. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
10. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
11. XTL Receives Staff Letter From NASDAQ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... launch of the Supplyframe Design Lab . Located in Pasadena, Calif., the ... future of how hardware projects are designed, built and brought to market. , ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData Security announced ... new role of principal product architect and that ... director of customer development. Both will report directly ... officer. The moves reflect NuData,s strategic growth in ... to high customer demand and customer focus values. ...
(Date:6/9/2016)... 2016  Perkotek an innovation leader in attendance control systems is proud to announce ... for employers to make sure the right employees are actually signing in, and to ... ... ... ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
Breaking Biology News(10 mins):